-
2 February 2012 - Paris (France)
Ipsen’s fourth quarter and full year 2011 sales and other significant developments
-
27 January 2012 - Paris (France)
Ipsen acknowledges Tanakan® delisting in France
-
24 January 2012 - Paris (France)
Santhera and Ipsen Renegotiate Fipamezole Licensing Agreement
-
23 January 2012 - Paris (France)
Fifth meeting in the “Biological Complexity” series jointly organised by the Fondation Ipsen and the Salk Institute for Biological Studies
-
5 January 2012 - Dijon and Paris (France)
Oncodesign and Ipsen enter into a research collaboration for the development of new therapeutic agents against the LRRK2 Parkinson's disease target
-
4 January 2012 - Paris (France)
Ipsen announces its corporate agenda for 2012